


The Invesco Perpetual Monthly Income Plus Fund aims to achieve a high level of income whilst seeking to maximise total return through investing in high yielding corporate and Government bonds, together with UK equities.
| Name | % Net Assets |
|---|---|
| AstraZeneca | 6.2% |
| UK Treasury | 3.1% |
| Linde 8.125% £ Bonds 14/7/2016 | 2.6% |
| SLM 5.375% £ Bonds 15/12/2010 | 2.6% |
| UPC | 2.4% |
| Rhodia € FRN 15/10/2013 | 1.1% |
| Rexam 6.75% € Bonds 29/6/2017 | 1.1% |
| BG | 1.0% |
| Intergen 9.5% £ Bonds 30/6/2017 | 1.0% |
| Reynolds American | 1.0% |
| Key | % Net Assets |
|---|---|
| 6.2% | |
| 3.1% | |
| 2.6% | |
| 2.6% | |
| 85.5% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 429.11p |
| Currency | GBP |
| Change | 0.88p |
| % | 0.21% |
| YTD change | 15.87p |
| YTD % | 3.84% |
| Fund Inception | 06/02/1999 |
|---|---|
| Fund Manager | Paul Causer / Paul Read / Neil Woodford |
| TER | 1.44 (31-Dec-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | £100 |
| Savings | £20 |
| Charges | |
|---|---|
| Initial | 5.00% |
| Annual Mang't | 1.42% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.00 |
| Sharpe ratio | 0.52 |
You are here: research